Bharat Book Bureau

In a new edition of their report ‘Mobile Broadband Cards, Routers, Services, and Subscribers’ Infonetics Research predict mobile broadband cards to be an $8.4 billion market by 2013.

Report highlights:

The mobile broadband card market grew 10% sequentially in the first half of 2009, driven by increasing adoption of HSPA and demand for netbooks

Manufacturer revenue from mobile broadband cards is forecast to hit $8.4 billion worldwide by 2013

Worldwide, the number of mobile broadband subscribers is expected to near 1 billion by 2013 (including phone and PC based W-CDMA/HSPA, CDMA2000/EV-DO, and LTE subscribers)

Mobile subscriber growth is being fueled by people seeking basic voice service, particularly in BRIC countries (Brazil, Russia, India, China), all migrating to 3G, which in turn will drive mobile broadband subscriber adoption

CDMA operators have been quicker off the blocks with mobile broadband, rolling out EV-DO earlier than GSM operators upgraded their networks to W-CDMA/HSPA, resulting in significantly higher CDMA2000/EV-DO mobile broadband card adoption

Between 2009 and 2013, worldwide service provider revenue from mobile broadband services is forecast to more than double

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Mobile-Broadband-in-Emerging-Europe.html

Batteries Supercapacitors Alternative Storage for Portable Devices

New technologies call for different forms of battery
Electronics and electrics are becoming ubiquitous, the devices appearing on and in higher and higher volume products including e-labels and e-packaging. This calls for different forms of battery, capacitor and other energy storage because priorities such as environmental credentials, thinness and compatibility with energy harvesting (eg solar cells) come to the fore alongside life and cost. This unique new report is directed towards those developing, marketing and using the new small electronic and electrical devices, particularly those that are self-sufficient. It will also interest those investing in new battery, capacitor and allied companies providing products for these markets and those regulating and supporting these burgeoning industries. To this end, the report is almost devoid of equations but it is replete with summary diagrams and tables, pros and cons, company profiles, new products and applications beyond the familiar ones. There is therefore much to interest those with a technical background as well. The report looks hard at what comes next, particularly over the next ten years.

Designed for a broad range of readers
We use relatively simple language so the report can be useful to as broad a range of readers as possible, enhanced by a glossary. After all, investors, government regulators, journalists and many other people have a great interest in the imminent huge deployment of small self-powered electronic and electrical devices. It will eventually reach hundreds of billions of products yearly, including electronically enhanced drug packs, magazines, disposable medical testers and much more besides. For the more technical, there are many new summary tables and diagrams comparing parameters required and achieved. The parameters, including costs, and the applications are compared and the work of many suppliers is evaluated. No other report on this subject is as broad ranging or up to date. The main emphasis is on what will needed and possible, not on rehearsing the story of traditional cylindrical, laptop and mobile phone batteries. Here we see the future.

Largest mobile energy storage market today
Energy storage for small devices, the subject of this report, forms by far the largest mobile energy storage market today, being much larger and faster growing than the market for heavy energy storage such as automotive and enjoying greater innovation for the future, including transparent and printed batteries. The report mainly concentrates on batteries and capacitors - including the rapid adoption of supercapacitors and hybrids of the two. It explains how they are constructed, how they work and the pros and cons. However, it also touches on the elusive small fuel cells and other options. Focussing on use in small devices, we forecast the market for both single use and rechargeable batteries by numbers and value from 2009-2019 and the market size for supercapacitors, tracking a return to rapid growth from 2010, after the global financial meltdown ends. The market drivers are given as they change over the years. We evaluate the limitations of current devices against what will be needed and what can be done. For example, as the traditional parameters of batteries and capacitors are painfully and slowly improved, some completely different improvements are proving exciting because they can open up completely new markets. These include transparent, edible, stretchable, woven, stitchable, implantable, biodegradable and wide area versions more suited to the world of ubiquitous electronics that is arriving. As wall decoration, windows, apparel, books, posters, consumer goods, pharmaceutical packaging , the sensing skin of an aircraft and the inside of a car and much more become electronic and local harvesting of power becomes commonplace, these are the products we need. We describe the remarkable new approaches including batteries assembled using viruses and carbon nanotubes, biomimetic and magnetic spin batteries and ones that can harvest energy in the human body. Then there are batteries and supercapabatteries only one tenth of a millimeter thick. Which are the most exciting developers and what will be available when? It is all here.

For more please visit
http://www.bharatbook.com/Market-Research-Reports/Batteries-Supercapacitors-Alternative-Storage-for-Portable-Devices.html

Medical Nanotechnology Markets

Nanotechnology has reached critical mass. Nowhere is this more evident than in medicine. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare. According to U.S. National Science Foundation estimates, by 2015 the annual global market for nano-related goods and services will top $1 trillion, thus making it one of the fastest-growing industries in history. Assuming that these figures prove to be accurate, nanotechnology will emerge as a larger economic force than the combined telecommunications and information technology industries at the beginning of the technology boom of the late 1990s.

This TriMark Publications report covers the specific segments of the medical nanotechnology markets, with particular emphasis on those segments where this emerging technology is or shows the potential to be most impactful. Nanotechnology, a field of science and technology that aims to control matter at the atomic, molecular and macromolecular level, potentially has far-reaching and paradigm-shifting implications for biology, drug discovery and medical technologies. The discipline has already yielded healthcare discoveries that have been used for drug delivery and diagnostic purposes. In this study, we describe various nanotechnologies under development for biological and medical purposes and assess their potential. Moreover, this analysis is arranged to provide an overview of the regulatory issues faced by the medical nanotechnology industry and focuses on how specific segments within the industry are poised for high future growth.

Table of Contents:

1 Overview 6
1.1 Statement of Report 6
1.2 About This Report 6
1.3 Scope of the Report 8
1.4 Methodology 8
1.5 Executive Summary 10

2 Medical Products (Drugs, Devices and Nutraceuticals) Nanotechnology Markets 13
2.1 Background 13
2.2 Market Calculations 13
2.3 Market Demands 14
2.4 Market Overview 18
2.4.1 The Role of Nanotechnologies in Medicine 18
2.4.2 Nanotechnology Sector Challenges 21
2.4.3 Nanotechnology Sector Drivers 21
2.4.4 Nanotechnology Sector Restraints 21
2.5 Nanotechnology Medical Product Market Segments 21
2.5.1 Overview 21
2.5.2 World Markets 22
2.5.3 U.S. Market 24
2.5.4 European Market 25
2.5.5 Japanese Market 26
2.5.6 Asian Market 27
2.5.7 Middle East 29
2.5.8 ROW 30

3 Medical and Life Science Nanotechnology Markets 32
3.1 Nano-Particles 33
3.2 Market for Nano-Particles in Life Sciences and Medicine 34
3.2.1 Key Players 34
3.2.2 Application Manufacturers 36
3.3 Dendrimers 36
3.3.1 PAMAM Dendrimers 36
3.3.2 Market for Nanocapsules in Life Sciences and Healthcare 37
3.3.3 Key Players 37
3.4 Market for Nanoporous and Nanostructured Materials in Life Sciences and Healthcare 37
3.4.1 Key Players 37
3.4.2 Nanofiltration 38
3.5 Nanodevices, Nanosensors and Quantum Dots 38
3.5.1 Sector Overview 38
3.5.2 Market for Quantum Dots in Life Sciences and Medicine 39
3.5.3 Commercial Applications for Quantum Dots 39
3.5.4 Key Players 40
3.5.5 Nanomaterials Suppliers 41
3.5.6 Application Manufacturers 41
3.6 Nanocoatings 42
3.7 Nanocomposites 42
3.8 Nanoarrays 42
3.8.1 Bead NanoArrays: A High-Sensitivity Detection System 43
3.9 Fullerenes 43
3.9.1 Key Applications and Market Opportunities 44
3.9.2 Medical Market Uses for Carbon Nanotubes 44
3.9.3 Key Players, Including Application Manufacturers, End Users and Nanomaterials Suppliers 45
3.10 Liposome-like Nano-Particles 45
3.10.1 Nanostructured Lipid Carriers 46
3.10.2 DauxoXome® Liposomal Formulation 46
3.11 Nanosensors 46
3.11.1 Microcantilever Sensors and Photonic Sensors 46
3.11.2 Field-Effect Nanoplate Devices 46
3.11.3 Electrochemical-Transducing Electrode Systems 47

4 Technology Issues 48
4.1 Nanotechnology in Drug Delivery and Development 48
4.1.1 Drug Delivery Using Nanotechnology 50
4.1.2 Design of Nanotechnology-Based Drug Delivery Systems 52
4.1.3 Using Magnetic Nano-Particles in Targeted Drug Delivery 53
4.1.4 Cancer Drug Delivery 53
4.1.5 Nano-Particle-Mediated Delivery of siRNA 55
4.1.6 Targeting Angiogenesis with Nano-Particles 55
4.1.7 Nanosystems and Inflammation 56
4.1.8 The Chiral Drug Development Process 56
4.1.9 Reasons Why the Drug Delivery Market is Rapidly Expanding 57
4.2 Categories of Medical Nanotechnology Products 57
4.2.1 Surgical Steel Devices 58
4.2.2 Contrast-Enhancing Agents for MRI (Magnetic Resonance Imaging) 58
4.2.3 Wound Dressings / Anti-Microbial Textiles 59
4.2.4 Nanocoated Surgical Blades 59
4.2.5 Suture Needles and Microneedles 59
4.2.6 Catheters for Minimally-Invasive Surgery 59
4.2.7 Optical Nanosurgery 59
4.2.8 Nanocoated or Nanocontoured Implant Surfaces 60
4.3 Biosensors and Biodetection 60
4.3.1 Cantilever Arrays 60
4.3.2 Nanosensors 60
4.3.3 Optical Sensors 60
4.3.4 Nano-Particle Sensors and Detectors 61
4.3.5 In Vitro Diagnostics 61
4.3.6 Imaging, In Vivo Diagnosis and Theranostics 64
4.4 Vaccines-Virus-Like Particles (VLPs) 65
4.5 Transdermal Drug Delivery 65
4.6 Phage Microarrays 65
4.7 Neuroscience 66
4.8 Nanotechnology Materials for Medical Products 67
4.8.1 Dental Materials 67
4.8.2 Bone Replacement 68
4.8.3 Contact Lenses 68
4.9 New Drug Development 68
4.10 Future Directions 69
4.10.1 Sources of Nano Development 69
4.10.2 Commercialization 70
4.10.3 Current/Pending Clinical Trials on New Products and Emerging Technologies 70
4.10.4 Future Directions 72
4.11 Key Technology Findings for Medical Uses of Nanotechnology 72

5 Business Trends 74
5.1 Market Forces 74
5.1.1 Market Drivers 74
5.1.2 Market Restraints 74
5.1.3 Medical / Clinical Studies 74
5.1.4 Demographics 75
5.2 Market Prospects 75
5.3 Marketing and Distribution 75
5.4 Competitive Landscape 76
5.5 Business Developments 76
5.5.1 Drug Pedigrees 76
5.6 Acquisitions and Partnerships 77
5.7 Key Players 77
5.8 Patent Climate 77
5.9 Investment Climate 78
5.9.1 U.S. Government 79
5.9.2 Europe 80
5.10 Venture Capital Environment 80
5.10.1 Medical and Health Nanotech Venture Companies 81
5.10.2 Pharma and Biotech Nanotech Venture Companies 83
5.11 Business Strategies for Medical Nanotechnology 88
5.12 Nanotechnology Questions 90
5.12.1 What Are the Near-Term Business Opportunities in the Medical Nanotechnology Markets? 90
5.12.2 What Are the Business Models Currently Used by Companies in the Medical Nanotechnology Markets? 90
5.12.3 How Will Manufacturers, Researchers, Physicians, Patients and Payers Influence the Medical Nanotechnology Markets? 91
5.12.4 What Are the Drivers and Bottlenecks Influencing the Medical Nanotechnology Markets? 91
5.12.5 What Are the Current and Emerging Technologies used in the Medical Nanotechnology Markets? 91
5.12.6 Who Holds the Proprietary Rights to the Medical Nanotechnology Markets, Especially in such a Multidisciplinary Environment? 92
5.12.7 What Are Current Applications of These Technologies? 92
5.12.8 What Regulatory Processes Must Medical Nanotechnology Undergo in the U.S., Japan and Europe? 92
5.12.9 How Will New or Emerging Medical Nanotechnologies Change Treatment and Payment Paradigms? 92
5.12.10 How Will Medical Nanotechnologies Reduce Adverse Clinical Reactions and Decrease Total Patient Care Cost? 93
5.12.11 How Will Medical Nanotechnology Reduce Healthcare Expenditures? 93
5.12.12 How Will Medical Nanotechnology Decrease Patient Diagnostic Testing Costs? 93
5.12.13 What is the Role of Nanotechnology in Drug Development? 93
5.12.14 Which Medical Nanotechnology Product Categories Are Driving Growth? 94
5.12.15 How Are Biomarkers Being Developed Using Nanotechnology? 94
5.12.16 What Companies Are Developing Nanotechnology Drug Delivery Systems? 94
5.12.17 How Are Nano-Optical Tagging Technologies Used in Animal Drug Safety Assessment Studies? 94
5.12.18 What Nanotechnology Platforms Are Being Used in Point of Care Diagnostic Testing? 95

6 Technology Assessment 96
6.1 Current Technologies for Nano 96
6.1.1 Nanodiagnostics 96
6.1.2 Competitive Analysis of Nano-Particle Assays 99
6.1.3 In Vivo Imaging 99
6.1.4 In Vitro Clinical Diagnostics 99
6.2 Future Technologies 101
6.3 Technology Accelerators, Roadblocks and Challenges 103
6.3.1 Technology Accelerators 103
6.3.2 Technology Roadblocks and Challenges 103
6.3.3 Public Awareness 104
6.4 Nanotechnology Product Trends and New Concepts for Medical Applications 106
6.4.1 Market Trends-Diagnostics 106
6.4.2 Market Trends-Therapies 115
6.4.3 Market Trends-Preventive and Other 120
6.4.4 Nanofibers in Medical Applications 124
6.4.5 Dental Applications 125
6.4.6 Optical Applications 126
6.5 Production Methods 126

7 Medical Nanotechnology Market Regulation and Reimbursement 128
7.1 Market Segments 128
7.1.1 Diagnostics 128
7.1.2 Therapies 128
7.1.3 Preventive 128
7.2 Customer Needs 128
7.3 Competitor Analysis 128
7.4 Pricing Pressures 129
7.5 U.S. Medicare and Other Government Agency Issues 129
7.6 Third-Party Reimbursement 129
7.7 Regulatory Trends 129
7.7.1 Regulatory Policy for Nanotechnology Drugs and Medical Devices 130
7.7.2 Current Good Manufacturing Practices (cGMPs) 133
7.7.3 Current Progress 134
7.7.4 Future Regulatory Trends 134
7.7.5 Key Issues 136
7.7.6 Labeling Requirements 136
7.8 Government Initiatives 136
7.8.1 NNI Research Centers 137
7.8.2 NNI Centers and Networks of Excellence 137
7.8.3 FDA’s Nanotechnology Task Force 137
7.8.4 Dutch Government Nano Action Plan 138
7.8.5 Other Research Centers 138
7.9 Medical Regulatory and cGMPs Issues 139
7.10 New Technology Concerns 140
7.11 Use Environment 141
7.11.1 Cancer 141
7.11.2 Medical Review 141
7.12 Risk Assessment 141
7.12.1 Risk Management (ISO 14971:2007) 141
7.12.2 Toxicology Assessment 141
7.12.3 Safety Evaluation 142
7.13 Cautions for Medical Nanotechnology Platforms 144
7.13.1 ETUC Precautionary Principle Applied to Nanotechnologies 145
7.13.2 Possible Risks to Human Health from Nanotechnology Products 145

8 Corporate Profiles 146
8.1 Abbott Laboratories 146
8.2 Abraxis Biosciences 146
8.2.1 NDA Pipeline 147
8.3 Aduro BioTech 148
8.4 Advanced Magnetics (AMAG Pharmaceuticals) 148
8.5 Alnis BioSciences 149
8.6 APP Pharmaceuticals 149
8.7 Arrowhead Research Corporation 150
8.8 Baxter International 151
8.9 Bristol-Myers Squibb 151
8.10 Caliper 151
8.11 Capsulution NanoScience AG 152
8.12 CytRx Corporation 152
8.13 Dendritech, Inc. 152
8.14 Dendritic Nanotechnologies, Inc. 152
8.15 Dow Chemical 153
8.16 DuPont 153
8.16.1 The Framework 155
8.17 Elan Drug Delivery (see also Bristol-Myers Squibb) 156
8.18 Evident Technologies 157
8.19 Evolved Nanomaterial Sciences (ENS) 157
8.20 Flamel Technologies 157
8.21 General Electric 160
8.22 GlaxoSmithKline 160
8.23 Honeywell International 160
8.24 Invitrogen 161
8.25 Nano-C 162
8.26 Nanocyl SA 163
8.27 Nanogen, Inc. 163
8.28 Nanolab Systems 164
8.29 NanoPass Technologies, Ltd. 164
8.30 Nanophase Technologies Corporation 164
8.31 Nanospectra Biosciences 165
8.32 Nanosphere, Inc. 165
8.33 Nanosys 166
8.34 New England Precision Grinding (NEPG) 166
8.35 Novartis 167
8.36 Novavax 167
8.37 Nucryst (Westaim) Pharmaceuticals 168
8.38 Orthovita 168
8.39 Phillips 168
8.40 pSivida Corporation 169
8.41 Quantum Dot Corporation 169
8.42 Roche 170
8.43 Sandvik Bioline 170
8.44 Starpharma Holdings, Limited 171
8.45 Sigma Aldrich 172
8.46 Wyeth Pharmaceuticals 173

9 Appendix: Nanotechnology References 174

10 Appendix: Glossary of Terms in Nanotechnology 175
10.1 Bionanotechnology 175
10.1.1 Nanopore Sequencing 175
10.1.2 Cantilevers with Functionalized Tips 175
10.1.3 Microneedles 175
10.1.4 Microchips for Drug Delivery 175
10.1.5 Nucleic Acid Lattices and Scaffolds 176
10.1.6 Nanofibers as Biomaterials 176
10.1.7 Carbon Nanotubes 177
10.2 Definition of Nano-Particles with Biological and Medical Applications 177
10.2.1 Superparamagnetic Iron Oxide Crystals 177
10.2.2 Quantum Dots 178
10.2.3 Dendrimers 178
10.2.4 Polymeric Micelles 178
10.2.5 Liposomes 178
10.2.6 Nanospheres 179
10.2.7 Aquasomes (Carbohydrate-Ceramic Nano-Particles) 179
10.2.8 Polyplexes/Lipopolyplexes 179

11 Appendix: NNI Centers and Networks of Excellence 180
11.1 National Science Foundation 180
11.2 Department of Energy 181
11.3 Department of Defense 181
11.4 National Aeronautics and Space Administration (NASA) 182
11.5 National Institute for Occupational Safety and Health 182
11.6 National Institute of Standards and Technology 182
11.7 National Institutes of Health 182

List of Figure :

Figure 2.1: End-User Markets for Nanotechnology, 2007 15
Figure 2.2: Nanometer Scale 18
Figure 2.3: International Per Capita Healthcare Spending by Country, 2006 22
Figure 2.4: World Nanomedical Market Shares, 2007 23
Figure 2.5: Total Spending on Healthcare in the U.S., 1960 to 2007 24
Figure 3.1: Nanotechnology Applications 33
Figure 3.2: Carbon Nanotubes 44
Figure 4.1: Depiction of nab Technology 49
Figure 7.1: FDA Product Validation Chart 133
Figure 7.2: FDA Product Lifecycle Model 135
Figure 8.1: Sigma Aldrich Sales Distribution 172

List of Table :

Table 2.1: Global Market for Nanotechnology Products, 2005 to 2013 15
Table 2.2: Nanotechnology Materials for Consumer Products, 2005 to 2013 16
Table 2.3: Nanotechnology Markets Worldwide by Industry, 2002 to 2015 16
Table 2.4: Nanotechnology Development Worldwide by Region, 2002 to 2015 16
Table 2.5: Currently-Growing Nanofabrication Techniques 18
Table 2.6: Global Nanomedicine Market, 2004 to 2013 22
Table 2.7: Nanomedicine Market Revenues by Product Segment, 2007 23
Table 2.8: Global Nanomedicine Market by Geographic Segment, 2004 to 2013 23
Table 2.9: U.S. Nanomedicine Market, 2004 to 2013 24
Table 2.10: European Nanomedicine Market, 2004 to 2013 25
Table 2.11: Japanese Nanomedicine Market, 2004 to 2013 26
Table 2.12: Japanese Nanotechnology Product Market Forecast 27
Table 2.13: Government Funding for Nanotechnology Research and Development, 1997 to 2008 30
Table 2.14: Global Nanotechnology R&D Spending, 1997 to 2013 30
Table 2.15: Global Growth in Nanotechnology R&D, 1997 to 2013 31
Table 3.1: Global Market for Nanotechnology Applications in the Life Sciences, 2005 to 2012 32
Table 3.2: Market for Nano-Particles in Life Sciences and Medicine, 2004 to 2012 34
Table 3.2: Market for Nanostructured Materials in Life Sciences and Medicine, 2004 to 2012 37
Table 3.4: Market for Nanodevices in Life Sciences and Medicine, 2004 to 2012 39
Table 3.5: Commercial Applications of Quantum Dots 40
Table 3.6: Market for Nanocomposites in Life Sciences and Medicine, 2004 to 2012 42
Table 3.7: Liposomal Formulations Used in Nanotechnology 45
Table 3.8: Types of Nanoparticulate Drug Delivery Systems 47
Table 4.1: FDA-Approved Drugs Developed with Nanotechnology-Based Formulations 49
Table 4.2: Key Effectors of Drug Delivery Using Nanomaterials 50
Table 4.3: Nanoscale Applications for Drug Delivery in Pharmaceutical Drug Development 51
Table 4.4: Drug Delivery Nanotechnology Market Drivers Ranked in Order of Impact 51
Table 4.5: Drug Delivery Nanotechnology Market Restraints Ranked in Order of Impact 51
Table 4.6: Anti-Cancer Drugs Formulated Using Nanomaterials 54
Table 4.7: Nanomaterials for in vitro RNAi Delivery 54
Table 4.8: Use of Peptide-Based Nanotubes for Biological Active Targets 55
Table 4.9: Lab-on-Chip and Microfluidic Chip Technology Innovations 62
Table 4.10: Diagnostic Nanotechnology Market Drivers Ranked in Order of Impact 63
Table 4.11: Diagnostic Nanotechnology Market Restraints Ranked in Order of Impact 63
Table 4.12: FDA-Approved In Vivo Imaging Materials Developed with Nanotechnology-Based Formulations 64
Table 4.13: Application Areas for Phage Nanotechnology Platforms 66
Table 4.14: Application Areas for Neuroscience Nanotechnology Platforms 66
Table 4.15: Nanotechnology Application Areas for Medical Nanomaterials 67
Table 4.16: FDA-Approved Dental Biomaterials Developed with Nanotechnology-Based Formulations 68
Table 4.17: Drug Discovery Nanotechnology Market Drivers Ranked in Order of Impact 68
Table 4.18: Drug Discovery Nanotechnology Market Restraints Ranked in Order of Impact 68
Table 4.19: Examples of Proposed U.S. NNI Interagency Collaborative Activities 70
Table 5.1: Medical Nanotechnology Market Drivers-Global, 2008 to 2016 75
Table 5.2: Medical Nanotechnology Market Restraints-Global, 2008 to 2016 75
Table 5.3: U.S. Nanotechnology Patents Issued per Year, 1996 to 2006 78
Table 5.4: Sources of Nanotechnology Funds 79
Table 5.5: National Government Funding Leaders for Nanotechnology, 2007 79
Table 5.6: Total Investments in Venture-Backed Nanotechnology Companies, 1997 to 2008 81
Table 5.7: Leading Nanotechnology Start-Up Companies 81
Table 6.1: Summary of Key Advantages for Nanotechnology 96
Table 6.2: Nanotechnology Platforms Used for Diagnostics and Imaging 96
Table 6.3: FDA-Approved In Vitro Diagnostics Developed with Nanotechnology-Based Formulations 97
Table 6.4: Applications of Veridex Nanotechnology Platform for Diagnostic Assays 98
Table 6.5: Characteristics of Gold Nano-Particle Technology for Diagnostic Testing 100
Table 6.6: Overview of Future Nanomedical Technology Development 101
Table 6.7: Recent Developments in Nanotechnology for Drug Delivery and Drug Discovery 101
Table 6.8: Recent Developments in Nanomaterials and Nanotechnology-Based Devices 102
Table 6.9: Recent Nanotechnology Applications in Diagnostics 102
Table 6.10: Future Nanomedical Technology Platforms 102
Table 6.11: Additional Global Market Trends 127
Table 8.1: AMAG Nanotechnology Products and Candidates 149

For more info please visit
http://www.bharatbook.com/Market-Research-Reports/Medical-Nanotechnology-Markets-.html

Military communications remain an essential part of security operations. The technology extends in range from equipping military personnel with devices so they can communicate on operations to providing centralised systems for organising battle and security operations on land, sea and in the air. Today, all military forces rely heavily on sophisticated electronic communications systems, with technology transfer to and from civilian communications systems, both those in use and those in development. This reliance on advanced communications will increase year on year. You and your organisation must be fully informed of these developments.

For units out in the field, digital radio – such as the U.S. Military’s ambitious joint tactical radio system (JTRS) – promises improved, programmable communications links. That system extends beyond voice-only communications to include the exchange of data and video messaging during battle and security operations. For linking all these systems in reliable, high-performing and secure networks, satellite and high-bandwidth terrestrial communications will exert an increasingly sophisticated and important role in military operations from 2008 onwards. This new                report, Military Communications and COTS 2008, describes both the technologies and the relevant markets in detail, along with cost-effectiveness, with relevant data and informed opinion. This information is valuable to both defence procurement operations and to relevant technology providers.

At the heart of many emerging military communications systems are commercial-off-the-shelf (COTS) technologies, such as 3G and WiMax. Many military organisations are interested in the synergies and cost-savings from such products and technologies. The commercial opportunities for relevant technology providers are great,                concludes, especially as military spending continues to rise strongly in many countries around the world.

Why You Should Buy This Report :

This new                report offers a detailed study of communications products and technologies that are poised to influence military operations heavily over the next 5 years and beyond. Military Communications and COTS 2008 discusses the following aspects of that important market:

• The emerging technologies that are transforming military communications, with both technological and commercial aspects discussed
• Forecasts for the military communications market globally and in the leading US sector
• Discussion of military communications projects in 11 countries identified as being among the world’s largest defence markets, with data and analysis of prospects there for communications suppliers
• An analysis of the major agencies and bodies involved in defence communication design and procurement.

In light of the expected strong growth of the military communications sector from 2008-2013 and beyond, companies that are already active in communications technologies are well positioned to benefit from those opportunities. This report is relevant both to companies already specialising in military electronic applications and to those interested in military applications of existing technology. The technology may be already commercialised or still under development.

If you work in this industry then you really need to get to grips with this concept before you get left behind. Act today and order your copy of this innovative report.

To know more and to buy a copy of your report feel free to visit :  http://www.bharatbook.com/Market-Research-Reports/Military-Communications-and-COTS-2008-Analysing-the-Expanding-Defence-Related-Market-.html

Or

Contact us at:
Bharat Book Bureau
Tel:  +91 22 2757 8668
Fax: +91 22 2757 9131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com

Emerging drug delivery technologies aim to improve measures of safety, efficacy, convenience and compliance in both new and existing drug candidates and products. For currently marketed products, reformulations with new delivery technologies will extend the period of patent protection. New formulas will be key to boosting sales volume of large molecule products in chronic diseases where patient compliance surrounding dosing strategies and ease of administration are limitations on market growth. In R&D pipelines, novel applications of delivery technologies will expose new methods to reformulate failed or discontinued drugs and mask their unfavorable effects, expanding the market of potential drug candidates.

‘Delivery Mechanisms for Large Molecule Drugs’ is a new report that examines the future of the drug delivery technologies market, and the short, mid, and long-term growth dynamics which will underpin investment decisions. This report will measure the performance of leading drug delivery technologies applied within clinical R&D pipelines and identify when specific therapy area populations are set to benefit from emerging innovations. The market success of new technologies is forecast by their ability to fulfill unmet medical need, the maturity of the technology in clinical application, and the level of commercial interest and investment landscape.

Key Findings

Nanotechnology will have the greatest impact on the drug delivery market. However, the immaturity of the technology is likely to delay marketed presence over the next 7-10 years.
Antibody fragmentation and PEGylation technologies are the leading targeted large molecule particle engineering formulas with marketed drug product presence. However, antibody fragments have suffered 33 candidate failures compared with 12 PEGylated products.
Active transdermal technologies have generated the greatest number of technologies and devices amongst large molecule delivery innovations, with 16 clinical and 8 preclinical drug/device combination products and 49 stand-alone devices.
Electronic delivery is set to have the greatest impact upon the device industry. Electronic device control is more advanced within the field of pulmonary delivery than transdermal delivery, with the average pulmonary-based product in early clinical phase I compared to late-stage preclinical investigation for transdermal. There are, however, 25 transmembrane electroporation technologies currently being developed, in comparison to 12 for electronic active pulmonary delivery.
Use this report to…

• Understand the drivers of new delivery platform developments with this report’s analysis of therapy area growth drivers, clinical development spend and unmet clinical need.
• Identify the risks and opportunities associated with emerging delivery technologies by measuring the risk potential and maturity of innovative platforms.
• Evaluate the latest developments in systemic targeting technologies by using this report’s analysis of innovations and pipeline progress for the latest active and passive targeting techniques.
• Discover which technologies have the greatest potential within large molecule product markets in the future with this report’s comparative analysis of growth metrics for leading platforms and an evaluation of their established clinical drug application.
• Assess recent innovations in pulmonary delivery technologies and needle-free transdermal delivery with this report’s analysis of clinical and preclinical developments and commercial potential.

Explore issues including…

High failure rates for new technologies. The high failure rates of drugs to which pioneering delivery techniques have been applied have made investors cautious. Unknown clinical safety and efficacy profiles have made it harder to determine appropriate parameters for success in clinical application.
Immaturity of technologies. Many of the technology platforms profiled in this report are in the early stages of application to clinical drug candidates. Those that have achieved success in marketed drug candidates already have ‘next generation’ alternatives in technology pipelines.
Unknown clinical pharmacokinetics. Many of these platforms remain in such an immature stage that they have yet to be applied to drug candidates. In vivo experimental use in drug candidates can never accurately predict success once a technology has reached maturity. Even for those technologies with established use in R&D pipelines, long-term clinical efficacy remains unknown.
Regulation of the new technologies. While the clinical performance of new particle engineered drug molecules or active delivery devices remain unknown, regulatory bodies only have existing data-measure
demands on which to benchmark their expectations. This framework will be shifted in line with emerging clinical performance datasets.
Discover…

• Which delivery technologies will have the greatest impact on the large molecule market in the short, mid, and long-term?
• How mature are the different delivery technologies and what is their pipeline presence in terms of application to R&D drugs?
• Will particle engineering technologies drive injectable formulas to dominate the market?
• Which therapy areas will benefit most from growth in the different technologies?
• How can the risk-profiles associated with clinical use be most effectively minimized?
• What are the leading novel platforms?
• Who are the targets for out-licensing and co-development of platforms for clinical use?
• What are the leading technology platforms within different classifications and how have they achieved their growth?
Table of Contents:
 
 Delivery Mechanisms for Large Molecule Drugs
 Executive summary 10
 Introduction 10
 Drivers for new platform developments 11
 Resistors of change 12
 Key emerging technologies 13
 Systemic targeting technologies 14
 Ease of use systems 15
 Conclusions 16
 Chapter 1 Introduction 18
 Summary 18
 Introduction 19
 The emergence of large molecule therapeutics 21
 Definitions 23
 Technology platform definitions 23
 Product coverage 25
 Market coverage 25
 Leading technologies coverage 27
 The measures for market success 28
 Chapter 2 Drivers of new platform
 developments 30
 Summary 30
 Introduction 31
 The growth of the large molecule market 32
 Therapy area growth drivers 33
 Clinical development spend 35
 Cost-effective manufacturing 36
 Existing failure rates 36
 Unmet clinical needs 38
 Boosting patient compliance 39
 Overcoming stability, bioavailability and toxic effects 40
 Improving efficacy 40
 Chapter 3 Risk, costs and technology
 maturity 42
 Summary 42
 Introduction 43
 Risk of failure with new technologies 43
 Unknown drug candidate pharmacokinetics 45
 Solubility and instability with oral candidates 45
 Bioavailability 46
 Toxicity and unknown long-term effects 47
 The shifting regulatory framework 47
 Case study: Insulin delivery and investor confidence 48
 The impact of cost and revenue on the decision to innovate 51
 Immaturity concerns 52
 Maturity of the delivery technologies 52
 Chapter 4 Key emerging technologies 58
 Summary 58
 The forecast market impact 59
 Nanotechnology to enhance solubility profiles 60
 The evolving nanotechnology industry 61
 The development pipeline 63
 Leading clinical applications 64
 Parenteral delivery systems 66
 Dermal platform systems 67
 Nanostructured materials; oral and depot system use 68
 Novel oral drug delivery systems 68
 Investigative nanoshells, nanofilms and active control 69
 Advances in microelectronics 71
 Existing electronic applications 71
 The development pipeline for microelectronics 73
 Microchip technologies 73
 Inkjet technology for drug delivery 74
 Chapter 5 Systemic targeting techniques 78
 Summary 78
 Introduction 79
 Systemic passive targeting techniques 81
 Stealth technologies: Immune system evasion 81
 PEGylation technologies 83
 PEGylation in clinical pipelines 84
 Preclinical PEGylation investigation 86
 The limitations of PEG 86
 Next generation PEGylation 87
 Systemic active targeting techniques 88
 Antibody techniques 89
 Antibody fragments 90
 Binding specificity 91
 Novel combination technologies to improve targeting 92
 Cost-effective manufacture 93
 The development pipeline 94
 The emergence of IgG4 antibody therapies 94
 Small modular Immunopharmaceuticals as antibody alternatives 95
 Pipeline novel conjugate technologies 96
 Antibody fragments in targeted carrier systems 96
 Investigational protein carrier Prodrug complexes 97
 Clotting factor conjugate targeting 97
 Molecular trojan horse techniques 98
 Chapter 6 Ease of use systems 102
 Summary 102
 Introduction 103
 Pulmonary delivery technologies 104
 Particle engineering technologies for pulmonary delivery 105
 Vaporization techniques and delivery control 106
 Applications of electronics 106
 Needle-free transdermal delivery 107
 Leading technology platforms 109
 Needle-free pressure-based systems 110
 Microinjection platforms for intra-epidermal delivery 110
 EMEA filing for first microinjection system 111
 technology platform 112
 Electrotransport systems 113
 Electroporation in transdermal delivery 113
 TransPharma Medical ltd’s RF-Microchannel technology 114
 Novel approaches to active intra-epidermal delivery 115
 Laser drug delivery systems 115
 Thermal energy platform 116
 Chapter 7 Conclusions 118
 Summary 118
 Introduction 119
 Pharma vs biotech large molecule R&D investment 119
 Leading technologies 121
 Growth in particle engineering technologies 121
 The impact of new routes of administration 122
 Large molecule drug delivery market growth and maturity 123
 Current and future market impact 127
 Therapy area impact 127
 Timeline of impact 130
 Summary of technology success and impact 133
 Appendix 136
 Index 136
 Methodology 137
 Methodology 137
 MedTRACK platform identification 137
 Glossary 138
 
 List of Figures
 Figure 1.1: The role of drug delivery in the product R&D pipeline 20
 Figure 1.2: Biopharmaceutical company dependence on large molecule drugs* 22
 Figure 1.3: Defining the pathway from proprietary technology to clinical use 24
 Figure 2.4: The global pipeline for chemical and biologic drugs, October 2008 33
 Figure 2.5: Number of pipeline biologic drug candidates and products, by therapy area, October 2008 34
 Figure 2.6: Pharma R&D spend 2004-2009e 35
 Figure 2.7: Biotech R&D spend ($bn), 2004-2009e 36
 Figure 2.8: Pharmacokinetic effects; resistors of market growth and opportunity for new technologies 38
 Figure 3.9: Key innovative technologies, clinical drug failures and discontinued products, November 2008 44
 Figure 3.10: Development pipeline for insulin devices, human insulins and analogues, October 2008 49
 Figure 3.11: Discontinued insulin devices, human insulins and analogues, platforms for delivery, per year 2001-2008 51
 Figure 3.12: Key particle engineering technologies; industry size and maturity 54
 Figure 3.13: Key route of administration technologies; industry size and maturity 55
 Figure 4.14: Investment deals and clinical applications in nanotechnology drug delivery platforms, 2002-Q2 2008 62
 Figure 4.15: Product pipeline; large molecule nanotechnology innovations 64
 Figure 4.16: Maturity of electronic active delivery platforms in transmembrane and pulmonary delivery systems 72
 Figure 5.17: The market advantage of targeted drugs 80
 Figure 5.18: Passive targeting strategies for large molecule delivery 81
 Figure 5.19: The benefits of PEGylation to improve pharmacological profiles 83
 Figure 5.20: Active targeting strategies for large molecule delivery 88
 Figure 5.21: The global MAb product pipeline by phase, Q4 2008 89
 Figure 5.22: Antibody fragmentation platforms – Competitive advantage 90
 Figure 5.23: Antibody fragments: separating targeting domains 92
 Figure 6.24: Transdermal and transmembrane active platform technologies, November 2008 108
 Figure 6.25: Investment in and maturity of active transdermal delivery 109
 Figure 7.26: Big biotech v big pharma large molecule patent applications, 2003-2007, global 120
 Figure 7.27: Particle engineering technologies in drug R&D pipelines, by phase, October 2008 122
 Figure 7.28: Industry growth and investment, leading innovative drug delivery platforms 124
 Figure 7.29: Growth in technology deals; 1998-2007 126
 Figure 7.30: Impact of new technology platforms developments on therapy area pipelines 127
 Figure 7.31: Therapy area focus of innovative technology product candidates, October 2008 128
 Figure 7.32: New medical device technologies, anticipated market impact 129
 Figure 7.33: Emerging particle engineering technologies, anticipated market impact 130
 Figure 7.34: The impact of new delivery technologies; timeline for success 131
 Figure 7.35: Measures of technology success 133
 
 List of Tables
 Table 1.1: Nektar’s leading innovative technology pipeline 25
 Table 1.2: Needle free delivery; Key routes of administration 26
 Table 1.3: Technology market coverage 27
 Table 2.4: The global pipeline for chemical and biologic drugs, October 2008 37
 Table 3.5: Key innovative technologies, clinical drug failures and discontinued products,
 November 2008 45
 Table 3.6: Key route of administration technologies; industry size and maturity 56
 Table 4.7: Nanotechnology drug delivery platforms, large molecule vs small molecule
 applications, November 2008 63
 Table 4.8: Nanoparticles as drug delivery carriers 64
 Table 4.9: Leading clinical parenteral drug delivery 66
 Table 5.10: Clinical PEGylation stealth targeting technologies 84
 Table 5.11: Antibody fragment products, clinical applications 93
 Table 5.12: Armagen’s proprietary CNS product pipeline: Trojan horse conjugate delivery 99
 Table 6.13: Small molecule success of membrane transport technologies, November 2008 106
 Table 6.14: Clinical use electronic pulmonary delivery technologies 107
 Table 6.15: Transdermal and transmembrane active platform technologies, November 2008 108
 Table 6.16: Novel electroporation platforms; transdermal alternatives 113
 Table 7.17: Innovative technology products in R&D pipelines, October 2008 123
 Table 7.18: Industry maturity and investment, leading innovative drug delivery platforms 125
 Table 7.19: Growth in technology deals, 1998-2007 126
 Table 7.20: Therapy area focus of innovative technology product candidates, October 2008 129
 
For more information pls visit
http://www.bharatbook.com/Market-Research-Reports/Delivery-Mechanisms-for-Large-Molecule-Drugs-Successes-and-failures-of-leading-technologies-and-key-drivers-for-market-success.html

A new report by Global Markets Direct, the business intelligence specialists, finds that deepening economic crisis in most economies, cost effectiveness and technological advances is expected to lead to a high single digit growth rate in the global home healthcare equipment market. Global Markets Direct’s report, “The Future of the Global Home Healthcare Equipment Market to 2015”, highlights these developments as the key market drivers for the global home healthcare equipment market.

Global Home Healthcare Equipment Market to Grow In High Single Digits for the Next Seven Years
The global home healthcare market valued at $47.5 billion in 2008 is forecast to reach $86 billion in 2012 with an annual growth rate of 8.9%. Cost effectiveness of home as a healthcare setting, healthcare providers cost containment efforts, technological advances in telehealth, diabetes care devices, drug delivery devices, and respiratory devices and positive reimbursement policies from private and public healthcare insurance companies is fuelling the growth in the home healthcare market. The current economic crisis will continue to drive the growth in the global home healthcare equipment market.
Recipient’s dignity and independence, quality of life, supplemental care of family and friends play an important role in choosing home as the point of delivery for healthcare needs. Patients also play active and important role in their well being in the home healthcare settings.

Rising Healthcare Expenditures to Boost Home Healthcare Equipment Market
In developed countries like the US; hospital care, physician and clinical services, professional services, administrative expenses and drugs account for more than 3/4th of the total healthcare expenditure. Only 3% of the total expenditure is spent on home healthcare. In most developed countries and in some emerging economies like Taiwan, Korea and Russia, health insurance allows people to seek medical attention more often leading to increased doctor visits and hospital stays. This is in turn is raising the healthcare costs due to increased hospital stays, physician and nursing fees and other associated costs. As a counter initiative, insurers and government agencies have started increasing the amount of deductibles, reduced the coverage on doctor visits and in some cases the coverage for certain conditions are dropped altogether.  This is leading to more patients seeking home as their healthcare centre. The global economic downturn just compounds to the existing healthcare problems and will drive more and more people towards home as their healthcare centre.

Glucose Monitoring Systems, Positive Airway Pressure Devices, Self Testing IVD Devices, Infusion Systems and Insulin Delivery Systems to Drive the Growth in the Global Home Healthcare Equipment Market
Glucose monitoring systems, positive airway pressure devices, self testing IVD devices, infusion systems and insulin delivery systems grew at home healthcare equipment market growth rate of 6.5% and above historically and are forecast to grow above 8.9% for the next seven years. The growth is primarily driven by the ever increasing diabetes population, improved product lines, advent of minimally invasive and non-invasive devices, smaller and lighter weight of the devices.

Glucose monitoring systems and insulin delivery systems are the fastest growing segments in the global home healthcare equipment market with growth rate forecasts of 10.8% and 13.1% respectively for the next seven years. The market is increasingly driven by the consumable aspect of the blood glucose test strip and lack of alternatives for diabetes affected patients especially the insulin dependent type1 diabetes patients.

IVD Companies to Continue Focusing On Inorganic Growth Route
Siemens Medical Solutions’ acquisitions of Diagnostic Products Corp. and Bayer Diagnostics in 2006 and acquisition of Dade Behring Inc in November 2007 not only strengthened Siemens’s position in the market but also made it a strong contender to replace F.Hoffman La Roche as the market leader in future. Inverness Medical Innovations acquisition of Biosite Inc in May 2007 vaulted the company to a prominent position in the IVD market. In February 2008, F. Hoffman La Roche acquired Ventana Medical Systems to strengthen its leading position in the market. Inorganic growth has been the route of choice for companies to expand their product portfolio and increase revenues as evidenced by the recent acquisition of Olympus diagnostic operations by Beckman Coulter in February 2009.

Though most of the companies are focusing on the inorganic growth route to maintain or gain market share, they are also putting conscious and continuous efforts on product development to release more efficient, effective, accurate and faster responding devices. The reason companies are adopting this dual strategy is to keep up with the pace of the competition and acquisitions take time to mature and realize benefits which happens only over long term in majority of the cases.
Product Recalls Altering the Competitive Landscape in the Infusion Systems Market
Baxter market share has been continuously falling from its high of 28% in 2005 to 18% in 2007. Product recalls by Baxter International led to a fall in its market share with Cardinal Health emerging as a leader in the infusion systems market. Hospira, Inc. has been the major beneficiary in the reshuffling of the global market share of infusion systems with its market share increasing to 12.6% in 2007.

In the past three years, due to safety concerns regarding the usage of infusion systems made by Baxter International, Cardinal Health and Hospira, product recalls were initiated by the companies and the FDA. Of the three, Baxter International suffered heavy losses and bad publicity, which eventually led to product modification. Cardinal Health and Hospira had to recall only a single batch and also were able to keep the negative publicity of their recalled products to a very minimum level. Hospira saw this as a prime opportunity to cash in and expanded the sale of its infusion pumps at the expense of industry leader Baxter International by using aggressive marketing methods. 

For more information contact us at

Bharat Book Bureau
207, Hermes Atrium, Sector 11, PO Box.54, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com

Global Markets Direct’s “The Future of the Diabetes Care Devices Market to 2015” report provides key data, information and analysis on the global diabetes care devices market. The report provides market landscape, competitive landscape and market trends information on the glucose monitoring and insulin delivery market categories. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report reviews the competitive landscape in terms of mergers and acquisitions, pipeline products and technology offerings.
 
Scope
 
 -The report covers data and analysis on the diabetes care devices market in the leading geographies of the world comprising of the United States, Canada, UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
 -The report covers global market size and company share data for 2 diabetes care devices market categories – glucose monitoring and insulin delivery.
 -Annualized market revenues data from 2001 to 2008, forecast forward for 7 years to 2015.
 -The report provides qualitative analysis of market drivers, restraints, future outlook and challenges by categories and segments.
 -The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
 -Key topics covered include the global diabetes care devices M&A landscape, global market landscape in the continuous glucose monitor market and opportunity analysis of the emerging markets.
 -The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct’s team of industry experts.
 
Reasons to buy
 
 -Develop business strategies by understanding the trends and developments that are driving the diabetes care devices market globally.
 -Design and develop your product development, marketing and sales strategies.
 -Exploit M&A opportunities by identifying market players with the most innovative pipeline.
 -Develop market-entry and market expansion strategies.
 -Identify key players best positioned to take advantage of the emerging market opportunities.
 -Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
 -What’s the next being thing in the diabetes care devices market landscape? – Identify, understand and capitalize.
 -Make more informed business decisions from the insightful and in-depth analysis of the global diabetes care devices market and the factors shaping it.

Table of Contents:

1 Table Of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 The Future of the Diabetes Care Devices Market to 2015 9
2.1 Executive Summary 9
2.2 Diabetes Care Devices: Definitions 10
2.2.1 Glucose Monitoring 10
2.2.1.1 Blood Glucose Meters 10
2.2.1.2 Blood Glucose Test Strips 10
2.2.2 Insulin Delivery 10
2.2.2.1 Insulin Jet Injector 10
2.2.2.2 Insulin Pen 10
2.2.2.3 Insulin Pump 10
2.2.2.4 Insulin Syringes 10
3 Diabetes And Its Prevalence 11
3.1 Diabetes – A Look In To the Chronic Disease 11
3.1.1 Type 1 and Type 2 Diabetes 11
3.1.2 Diabetes Accentuating Cardiovascular Disease 11
3.1.2.1 Atherosclerosis 11
3.1.2.2 Diabetic Cardiomyopathy 11
3.1.2.3 Stroke 12
3.1.2.4 Renal Disease 12
3.1.3 Diabetes A Huge Strain on Healthcare Spending 12
3.1.4 Diabetes Prevalence 13
3.1.4.1 Diabetes Prevalence: Global 13
3.1.4.2 Diabetes Prevalence in Developing Nations 13
4 Diabetes Care Devices: Market Landscape Assessment 15
4.1 Diabetes Care Devices: Key Market Trends 15
4.1.1 Diabetes Care Devices: Growth Drivers 15
4.1.2 Diabetes Care Devices: Growth Restraints 15
4.1.3 Home Healthcare Driving Growth in the Diabetes Care Devices Market 16
4.1.4 The Future of Direct To Consumer (DTC) Marketing in Diabetes Care: Targeted Mass Media 17
4.1.5 Brand Loyalty in Diabetes Care Devices: Hard To Achieve 18
4.1.6 Reimbursement Issues Restraining The Market 18
4.1.7 Drug Stores to remain the major distribution channels 19
4.2 Diabetes Care Devices: Technological Trends 21
4.2.1 Enhancing Life 21
4.2.2 Continuous Glucose Monitoring (CGM) 21
4.2.3 Pain Free Monitoring Devices Will Drive Future Growth In The Diabetes Care Device Market 21
4.2.4 Increasing Demand For Pain Free Insulin Delivery Devices 22
4.2.5 Remote Monitoring: Increasing Diabetic Compliance 23
4.3 Diabetes Care Devices Cross Country Analysis 24
4.4 Diabetes Care Devices Cross Segment Analysis 26
5 Diabetes Care Devices: Market Sizing and Share Analysis 27
5.1 Market Overview 27
5.2 Diabetes Care Devices: Cross Geography Comparison 28
5.3 Diabetes Care Devices Competitive Landscape 29
5.3.1 Key M&A Deal in the Diabetes Care Devices Market: LifeScan and Bayer Healthcare’s agreement with Medtronic 30
6 Glucose Monitoring Market Landscape 31
6.1 Market Overview 31
6.2 Glucose Monitoring Market: Cross Geography Analysis 32
6.3 Glucose Monitoring Market: Competitive Landscape 34
6.4 Blood Glucose Meters Market Landscape 35
6.4.1 Blood Glucose Meters Market Value 35
6.4.2 Blood Glucose Meters Market: Cross Geography Comparison 36
6.4.3 Blood Glucose Meters Market Volume 37
6.4.4 Blood Glucose Meters Market Dynamics 39
6.4.4.1 Market Drivers 39
6.4.4.2 Market Restraints 39
6.5 Blood Glucose Test Strips Market Landscape 40
6.5.1 Blood Glucose Test Strips Market Value 40
6.5.2 Blood Glucose Test Strips Market: Cross Geography Comparison 41
6.5.3 Blood Glucose Test Strips Market Volume 43
6.5.4 Blood Glucose Test Strips Market Dynamics 44
6.5.4.1 Market Drivers 44
6.5.4.2 Market Restraints 44
6.6 Glucose Monitoring Key Pipeline Products 45
7 Insulin Delivery Market Landscape 48
7.1 Market Overview 48
7.2 Insulin Delivery Market: Cross Geography Comparison 50
7.3 Insulin Delivery Systems Market: Competitive Landscape 51
7.4 Insulin Jet Injectors Market Landscape 52
7.4.1 Insulin Jet Injectors Market Value 52
7.4.2 Insulin Jet Injectors Market: Cross Geography Comparison 54
7.4.3 Insulin Jet Injectors Market Volume 55
7.4.4 Insulin Jet Injectors Market Dynamics 56
7.4.4.1 Market Drivers 56
7.4.4.2 Market Restraints 56
7.5 Insulin Pumps Market Landscape 57
7.5.1 Insulin Pumps Market Value 57
7.5.2 Insulin Pumps Market Volume 58
7.5.3 Insulin Pumps Market: Cross Geography Comparison 60
7.5.4 Insulin Pumps Market Dynamics 61
7.5.4.1 Market Drivers 61
7.5.4.2 Market Restraints 61
7.6 Insulin Pens Market Landscape 62
7.6.1 Insulin Pens Market Value 62
7.6.2 Insulin Pens Market Dynamics 63
7.6.2.1 Market Drivers 63
7.6.2.2 Market Restraints 63
7.7 Insulin Syringes Market Landscape 64
7.7.1 Insulin Syringes Market Value 64
7.7.2 Insulin Syringes Market: Cross Geography Comparison 65
7.7.3 Insulin Syringes Market Dynamics 66
7.7.3.1 Market Drivers 66
7.7.3.2 Market Restraints 66
7.8 Insulin Delivery Key Pipeline Products 67
8 Future Outlook 68
9 Appendix 69
9.1 Decision Support Database 69
9.1.1 Complications with Diabetes 70
9.2 Methodology 71
9.2.1 Coverage 71
9.2.2 Secondary Research 72
9.2.3 Primary Research 72
9.2.4 Models 73
9.2.5 Forecasts 73
9.2.6 Expert Panels 73
9.3 Contact US 74
9.4 Disclaimer 74

1.1 List of Tables
Table 1: Diabetes Prevalence Rates, 2007 13
Table 2: Population With Diabetes (mn), Developing Nations, 2025 14
Table 3: Home Healthcare Equipment Market, Global, Cross-segment Analysis, 2001 – 2015 17
Table 4: Total Cost, Traditional Glucose Meter Vs Continuous Glucose Monitor 19
Table 5: Non Invasive Glucose Monitoring Products 22
Table 6: Pain Free Insulin Delivery Products, 2008 23
Table 7: Diabetes Care, Cross Country Analysis, 2001 - 2015 25
Table 8: Diabetes Care Devices, Cross Segment Analysis, 2001 - 2015 26
Table 9: Diabetes Care Devices, Revenue ($ m), Global, 2001 - 2015 28
Table 10: Diabetes Care Devices, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 29
Table 11: Glucose Monitoring, Revenue ($ m), Global, 2001 - 2015 32
Table 12: Glucose Monitoring, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 33
Table 13: Blood Glucose Meters, Revenue ($ m ), Global, 2001 - 2008 36
Table 14: Blood Glucose Meters, Revenue ($ m ), Global, 2008 - 2015 36
Table 15: Glucose Meters, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 37
Table 16: Glucose Monitors, Volume (Units), Global, 2001 - 2008 38
Table 17: Glucose Monitors, Volume (Units), Global, 2008 - 2015 38
Table 18: Blood Glucose Test Strips, Revenue ($ m), Global, 2001 - 2008 41
Table 19: Blood Glucose Test Strips, Revenue ($ m), Global, 2008 - 2015 41
Table 20: Blood Glucose Test Strips, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 42
Table 21: Blood Glucose Test Strips, Volume (Units), Global, 2001 - 2008 43
Table 22: Blood Glucose Test Strips, Volume (Units), Global, 2008 - 2015 44
Table 23: Glucose Monitoring Key Pipeline Products 45
Table 24: Insulin Delivery, Revenue ($ m), Global, 2001 - 2015 49
Table 25: Insulin Delivery, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 50
Table 26: Insulin Injectors, Revenue ($ m), Global, 2001 - 2008 53
Table 27: Insulin Injectors, Revenue ($ m), Global, 2008 - 2015 53
Table 28: Insulin Jet Injectors, Revenue ($ m), Cross Geography Analysis, 2001 - 2015 55
Table 29: Insulin Injectors, Volume (Units), Global, 2001 - 2008 56
Table 30: Insulin Injectors, Volume (Units), Global, 2008 - 2015 56
Table 31: Insulin Pumps, Revenue ($ m), Global, 2001 - 2008 57
Table 32: Insulin Pumps, Revenue ($ m), Global, 2008 - 2015 58
Table 33: Insulin Pumps, Volume (Units), Global, 2001 - 2008 59
Table 34: Insulin Pumps, Volume (Units), Global, 2008 - 2015 59
Table 35: Insulin Pumps, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 60
Table 36: Insulin Pens, Revenue ($ m), Global, 2001 - 2008 62
Table 37: Insulin Pens, Revenue ($ m), Global, 2008 - 2015 63
Table 38: Insulin Syringes, Revenue ($ m), Global, 2001 – 2008 64
Table 39: Insulin Syringes, Revenue ($ m), Global, 2008 – 2015 65
Table 40: Insulin Syringes, Revenue ($ m), Cross Geographics Analysis, 2001 - 2015 66
Table 41: Insulin Delivery Key Pipeline Products 67
Table 42: Prevalence of Diabetes (Diagnosed And Undiagnosed), By Age Group, US, 2007 70

1.2 List of Figures
Figure 1: Home Healthcare Equipment Market, Global, Cross-segment Analysis, 2001 – 2015 16
Figure 2: Glucose Monitoring Devices, Distribution Channel Shares (%), 2008 20
Figure 3: Insulin Delivery, Distribution Channel Shares (%), 2008 20
Figure 4: Diabetes Care, Cross Country Analysis, 2001 - 2015 24
Figure 5: Diabetes Care Devices, Cross Segment Analysis, 2001 - 2015 26
Figure 6: Diabetes Care Devices, Revenue ($ m), Global, 2001 - 2015 27
Figure 7: Diabetes Care Devices, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 28
Figure 8: Diabetes Care Devices, Company Share (%), Global, 2008 30
Figure 9: Glucose Monitoring, Revenue ($ m), Global, 2001 - 2015 31
Figure 10: Glucose Monitoring, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 33
Figure 11: Glucose Monitoring, Company Share (%), Global, 2008 34
Figure 12: Blood Glucose Meters, Revenue ($ m ), Global, 2001 - 2015 35
Figure 13: Glucose Meters, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 36
Figure 14: Glucose Monitors, Volume (Units), Global, 2001 - 2015 38
Figure 15: Blood Glucose Test Strips, Revenue ($ m), Global, 2001 - 2015 40
Figure 16: Blood Glucose Test Strips, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 42
Figure 17: Blood Glucose Test Strips, Volume (Units), Global, 2001 - 2015 43
Figure 18: Insulin Delivery, Revenue ($ m), Global, 2001 - 2015 48
Figure 19: Insulin Delivery, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 50
Figure 20: Insulin Delivery, Company Share (%), 2008 51
Figure 21: Insulin Injectors, Revenue ($ m), Global, 2001 - 2015 52
Figure 22: Insulin Jet Injectors, Revenue ($ m), Cross Geography Analysis, 2001 - 20015 54
Figure 23: Insulin Injectors, Volume (Units), Global, 2001 - 2015 55
Figure 24: Insulin Pumps, Revenue ($ m), Global, 2001 - 2015 57
Figure 25: Insulin Pumps, Volume (Units), Global, 2001 - 2015 58
Figure 26: Insulin Pumps, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 60
Figure 27: Insulin Pens, Revenue ($ m), Global, 2001 - 2015 62
Figure 28: Insulin Syringes, Revenue ($ m), Global, 2001 – 2015 64
Figure 29: Insulin Syringes, Revenue ($ m), Cross Geographic Analysis, 2001 - 2015 65
Figure 30: Diabetes Incidence by Diagnosis, US, 2007 69
Figure 31: Diabetic Population by Treatment Type, US, 2007 70
Figure 32: Global Markets Direct Methodology 71
To know more and to buy a copy of your report please visit
http://www.bharatbook.com/Market-Research-Reports/Report-on-Future-of-the-Diabetes-Care-Devices-Market-to-2015-.html

“Wound Closure Devices Systems Pipeline Technology and Market Forecasts to 2015” report is an essential source of information and analysis on the global wound closure devices market. The report identifies the key trends shaping and driving the dynamism in the global wound closure devices market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. The report also analyses the M&A landscape in the global wound closure devices market with special focus on the market participants that have been the most M&A active. Most importantly, the report provides valuable insight on the pipeline products within the global wound closure devices sector.

Scope

-Annualized global wound closure devices market revenues data from 2001 to 2008, forecast forward for 7 years to 2015.
-Analysis and review of the key events and milestones that will impact the future of the global wound closure devices market. Each trend independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends.
-Insightful review of key industry drivers, restraints and challenges which are likely to impact the global wound closure devices market in the long run.
-In-depth analysis of the M&A landscape with a strong emphasis on the market players, likely to remain active in the near future.
-The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
-Comprehensive analysis of the most likely developments expected to bring a shift to the market positions of the leading manufacturers.
-The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Reasons to buy

-Develop business strategies by understanding the trends shaping and driving the global wound closure devices market.
-Identify key players best positioned to take advantage of the emerging market opportunities by developing insight on the prevalent and anticipated competitive landscape.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global wound closure devices market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-Support your go/non-go dilemma by identifying the markets that are least competitive and present significant opportunities for innovation and growth.
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Table of Contents:

1 Table Of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Wound Closure Devices Pipeline Technology And Market Forecasts To 2015 7
2.1 Wound Closure Devices- Definitions 7
2.1.1 Skin Closure Devices 7
2.1.2 Tissue Sealants 7
2.1.3 Hemostats 7
2.2 Executive Summary 8
3 Wound Closure Devices Technology Landscape 9
3.1 Wound Closure Devices: Overview 9
3.2 Wound Healing 10
3.3 Wound Closure Devices 11
3.3.1 Surgical staples 11
3.3.2 Skin closure tapes/strips 11
3.3.3 Fibrin Sealants 11
3.3.4 Skin adhesives 11
3.4 Wound Closure Devices Clinical Trials 12
4 Global Wound Closure Device Market 13
4.1 Market Overview 13
4.2 Wound Closure Devices: Cross Geography Analysis 15
4.3 Wound Closure Devices Market Trends 17
4.3.1 Wound Closure Devices Market Drivers 17
4.3.2 Wound Closure Devices Market Restraints 17
4.4 Competitive Landscape 18
5 Wound Closure Devices Pipeline Products 20
5.1 Pipeline Products by Geography 20
5.2 Pipeline Products by Development Stage 21
5.3 PleuraSeal Lung Sealant System 22
5.3.1 PleuraSeal Lung Sealant System Product Status 22
5.3.2 PleuraSeal Lung Sealant System Product Description 22
5.3.3 PleuraSeal Lung Sealant System Clinical Trials 23
5.4 TachoSil patch 24
5.4.1 TachoSil patch Product Status 24
5.4.2 TachoSil patch Product Description 24
5.5 Covastat 25
5.5.1 Covastat Product Status 25
5.5.2 Covastat Product Description 25
5.6 PRINEO Skin Closure System 26
5.6.1 PRINEO Skin Closure System Product Status 26
5.6.2 PRINEO Skin Closure System Product Description 26
5.7 CryoSeal Fibrin Sealant System 27
5.7.1 CryoSeal Fibrin Sealant System Product Status 27
5.7.2 CryoSeal Fibrin Sealant System Product Description 27
5.8 Evithorm 28
5.8.1 Evithorm Product Status 28
5.8.2 Evithorm Product Description 28
5.9 Wound Closure Devices Pipeline Products By Territory 29
5.10 Wound Closure Devices Pipeline Products By Development Stage 31
6 Global Wound Closure Devices Pipeline Product Summary 33
7 Global Wound Closure Devices Clinical Trial Summary 36
8 Future Outlook 37
9 Appendix 38
9.1 Research Methodology 38
9.2 Coverage 39
9.3 Secondary Research 39
9.4 Primary Research 40
9.5 Models 40
9.6 Forecasts 41
9.7 Expert Panels 41
9.8 GlobalData Consulting 41
9.9 Contact Us 41
9.10 Disclaimer 42

1.1 List of Tables

Table 1: Wound Closure Devices, Global, Value ($m), 2001 - 2008 14
Table 2: Wound Closure Devices, Global, Value ($m), 2008 - 2015 14
Table 3: Recent Wound Closure Devices Approval, US, 2008 18
Table 4: Key Acquisitions and Agreements in the Wound Closure Devices Market, 2003-2008 19
Table 5:      PleuraSeal Lung Sealant System, Product Status 22
Table 6:      PleuraSeal Lung Sealant System, Product Description 22
Table 7:      PleuraSeal Lung Sealant System Clinical Trial 1 23
Table 8:      TachoSil patch, Product Status 24
Table 9:      TachoSil patch, Product Description 24
Table 10:      Covastat, Product Status 25
Table 11:      Covastat, Product Description 25
Table 12:      PRINEO Skin Closure System, Product Status 26
Table 13:      PRINEO Skin Closure System, Product Description 26
Table 14:      CryoSeal Fibrin Sealant System, Product Status 27
Table 15:      CryoSeal Fibrin Sealant System, Product Description 27
Table 16:      Evithorm, Product Status 28
Table 17:      Evithorm, Product Description 28
Table 18: Wound Closure Devices Pipeline Products By Territory 29
Table 19: Wound Closure Devices Pipeline Products By Development Stage 31
Table 20: Global Wound Closure Devices Pipeline Product Summary 33
Table 21: Wound Closure Devices Pipeline Products By Clinical Trial 36

1.2 List of Figures

Figure 1: Wound Characteristics 9
Figure 2: Phases of Wound Healing 10
Figure 3: Wound Closure Devices, Global. Revenue ($m), 2001-2015 13
Figure 4: Wound Closure Device, Cross Geography Analysis, 2008 15
Figure 5: Wound Closure Devices Pipeline Products by Geography 20
Figure 6: Wound Closure Devices Pipeline Products by Development Stage 21
Figure 7: GlobalData Methodology 38
To know more and to buy a copy of your report please visit
http://www.bharatbook.com/Market-Research-Reports/Wound-Closure-Devices-Pipeline-Technology-and-Market-Forecasts.html

New technologies call for different forms of battery
Electronics and electrics are becoming ubiquitous, the devices appearing on and in higher and higher volume products including e-labels and e-packaging. This calls for different forms of battery, capacitor and other energy storage because priorities such as environmental credentials, thinness and compatibility with energy harvesting (eg solar cells) come to the fore alongside life and cost. This unique new report is directed towards those developing, marketing and using the new small electronic and electrical devices, particularly those that are self-sufficient. It will also interest those investing in new battery, capacitor and allied companies providing products for these markets and those regulating and supporting these burgeoning industries. To this end, the report is almost devoid of equations but it is replete with summary diagrams and tables, pros and cons, company profiles, new products and applications beyond the familiar ones. There is therefore much to interest those with a technical background as well. The report looks hard at what comes next, particularly over the next ten years.

Designed for a broad range of readers
We use relatively simple language so the report can be useful to as broad a range of readers as possible, enhanced by a glossary. After all, investors, government regulators, journalists and many other people have a great interest in the imminent huge deployment of small self-powered electronic and electrical devices. It will eventually reach hundreds of billions of products yearly, including electronically enhanced drug packs, magazines, disposable medical testers and much more besides. For the more technical, there are many new summary tables and diagrams comparing parameters required and achieved. The parameters, including costs, and the applications are compared and the work of many suppliers is evaluated. No other report on this subject is as broad ranging or up to date. The main emphasis is on what will needed and possible, not on rehearsing the story of traditional cylindrical, laptop and mobile phone batteries. Here we see the future.

Largest mobile energy storage market today
Energy storage for small devices, the subject of this report, forms by far the largest mobile energy storage market today, being much larger and faster growing than the market for heavy energy storage such as automotive and enjoying greater innovation for the future, including transparent and printed batteries. The report mainly concentrates on batteries and capacitors - including the rapid adoption of supercapacitors and hybrids of the two. It explains how they are constructed, how they work and the pros and cons. However, it also touches on the elusive small fuel cells and other options. Focussing on use in small devices, we forecast the market for both single use and rechargeable batteries by numbers and value from 2009-2019 and the market size for supercapacitors, tracking a return to rapid growth from 2010, after the global financial meltdown ends. The market drivers are given as they change over the years. We evaluate the limitations of current devices against what will be needed and what can be done. For example, as the traditional parameters of batteries and capacitors are painfully and slowly improved, some completely different improvements are proving exciting because they can open up completely new markets. These include transparent, edible, stretchable, woven, stitchable, implantable, biodegradable and wide area versions more suited to the world of ubiquitous electronics that is arriving. As wall decoration, windows, apparel, books, posters, consumer goods, pharmaceutical packaging , the sensing skin of an aircraft and the inside of a car and much more become electronic and local harvesting of power becomes commonplace, these are the products we need. We describe the remarkable new approaches including batteries assembled using viruses and carbon nanotubes, biomimetic and magnetic spin batteries and ones that can harvest energy in the human body. Then there are batteries and supercapabatteries only one tenth of a millimeter thick. Which are the most exciting developers and what will be available when? It is all here.

Table of Contents:

EXECUTIVE SUMMARY AND CONCLUSIONS
1. INTRODUCTION
1.1. Small electrical and electronic devices
1.2. What is a battery?
1.2.1. Battery definition
1.2.2. Battery history
1.2.3. Analogy to a container of liquid
1.2.4. Construction of a battery
1.2.5. Many shapes of battery
1.2.6. Single use vs rechargeable batteries
1.2.7. Challenges with batteries in small devices
1.3. What is a capacitor?
1.3.1. Capacitor definition
1.3.2. Capacitor history
1.3.3. Analogy to a spring
1.3.4. Capacitor construction
1.4. Limitations of energy storage devices
1.4.1. The electronic device and its immediate support
1.4.2. Safety
1.4.3. Improvement in performance taking place
1.5. Standards
2. RECHARGEABLE BATTERIES
2.1. Technology successes and failures
2.2. Lithium polymer vs lithium ion
2.3. New shapes - laminar and flexible batteries
2.3.1. Laminar lithium batteries
2.3.2. Ultrathin battery from Front Edge Technology
2.4. Transparent battery - NEC and Waseda University
2.5. New methods of charging
2.6. Technology Challenges
2.7. Threat to lithium prices?
2.8. New applications for new laminar rechargeable batteries
3. SINGLE USE BATTERIES
3.1. Tadiran Batteries twenty year batteries
3.2. Laminar printed manganese dioxide batteries
3.2.1. Printed battery construction
3.2.2. Printed battery production facilities
3.2.3. Applications of printed batteries
3.2.4. Printed battery specifications
3.3. Other emerging needs for laminar batteries - apparel and medical
3.3.1. Electronic apparel
3.3.2. Wireless body area network
3.4. Nanotube flexible battery
3.5. Biobatteries do their own harvesting
3.6. Microbatteries built with viruses
3.7. Biomimetic energy storage system
3.8. Magnetic spin battery
4. CAPACITORS AND SUPERCAPACITORS
4.2. Example of capacitor storage application - e-labels
4.3. Many shapes of capacitor
4.4. Capacitors for small devices
4.5. Technology of capacitors
4.5.1. Technology of non-polar capacitors
4.5.2. Technology of the electrolytic capacitor
4.5.3. Development path
4.6. Aluminum electrolytic capacitors
4.6.2. High capacitance but at a price
4.6.3. Non-polar electrolytic
4.6.4. Safety issues
4.6.5. Polarity
4.6.6. The dielectric is fragile
4.6.7. Electrolyte
4.7. Tantalum electrolytic capacitors
5. SUPERCAPACITORS = ULTRACAPACITORS
5.1. Where supercapacitors fit in
5.2. Advantages and disadvantages
5.3. How it all began
5.4. Applications
5.5. Uses in small devices.
5.6. Relevance to energy harvesting
5.6.1. Perpetuum harvester
5.6.2. Human power to recharge portable electronics
5.6.3. Use in nanoelectronics
5.7. Can supercapacitors replace capacitors?
5.8. Can supercapacitors replace batteries?
5.9. Electric vehicle demonstrations and adoption
5.10. How an ELDC supercapacitor works
5.10.1. Basic geometry
5.10.2. Properties of EDL
5.10.3. Charging
5.10.4. Discharging and cycling
5.10.5. Energy density
5.10.6. Achieving higher voltages
5.11. Improvements coming along
5.11.1. Better electrodes
5.11.2. Better electrolytes
5.11.3. Better carbon technologies
5.11.4. Carbon nanotubes
5.11.5. Carbon aerogel
5.11.6. Solid activated carbon
5.11.7. Carbon derived carbon
5.11.8. Graphene
5.11.9. Polyacenes or polypyrrole
5.12. Supercapacitor performance without EDL - EEstor
5.13. Supercabatteries or bacitors
6. FUEL CELLS AND OTHER ALTERNATIVES
6.1. Fuel cells
6.2. New forms of miniature fuel cells
6.2.1. Microbial fuel cells
6.2.2. Lightweight hydrogen generating fuel cell
6.2.3. Biomimetic approach with MIT fuel cell
6.3. Mechanical storage
7. ORGANISATION PROFILES
7.1. Blue Spark Technologies USA
7.2. Cap-XX Australia
7.3. Celxpert Energy Corp. Taiwan Head Quarter
7.4. Cymbet USA
7.5. Duracell USA
7.6. Enfucell Finland
7.7. Excellatron USA
7.8. Freeplay Foundation UK
7.9. Front Edge Technology USA
7.10. Frontier Carbon Corporation Japan
7.11. Harvard University USA
7.12. Hitachi Maxell
7.13. Holst Centre Netherlands
7.14. Infinite Power Solutions USA
7.15. Institute of Bioengineering and Nanotechnology Singapore
7.16. Lebônê Solutions South Africa
7.17. Massachusetts Institute of Technology USA
7.18. Matsushita Battery Industrial Company Ltd.
7.19. Maxwell Technologies Inc., USA
7.20. Nanotecture, UK
7.21. National Renewable Energy Laboratory USA
7.22. NEC Japan
7.23. Nippon Chemi-Con Japan
7.24. Oak Ridge National Laboratory USA
7.25. Planar Energy Devices USA
7.26. Power Paper Israel
7.27. Prelonic Technologies
7.28. Renata Batteries
7.29. ReVolt Technologies Ltd
7.30. Sandia National Laboratory USA
7.31. Solicore USA
7.32. Tadiran Batteries
7.33. Technical University of Berlin Germany
7.34. Sony Japan
7.35. University of California Los Angeles USA
7.36. University of Michigan USA
7.37. University of Sheffield UK
7.38. University of Wollongong Australia
7.39. Waseda University
8. MARKETS AND FORECASTS
8.1. Market for batteries, supercapacitors, other
8.2. Total global battery market
8.3. Global battery market by use
8.3.1. Batteries for RFID
8.3.2. Batteries for gift cards
8.3.3. Batteries for car keys
8.3.4. Printed and thin film batteries 2009-2019
9. GLOSSARY
APPENDIX 1: IDTECHEX PUBLICATIONS AND CONSULTANCY
APPENDIX 2 INTRODUCTION TO PRINTED ELECTRONICS
TABLES
1.1. Five ways in which a capacitor acts as the electrical equivalent of the spring
1.2. Advantages and disadvantages of some options for supplying electricity to small devices
1.3. Some limitations of batteries in small electronic devices and some solutions
3.1. Tadiran cylindrical battery ratings
3.2. Printed and thin film battery product and specification comparison
3.3. Printed battery materials comparison
3.4. The half cell and overall chemical reactions that occur in a Zn/MnO2 battery
4.1. Comparison of the three types of capacitor when storing one kilojoule of energy.
4.2. Examples of energy density figures for batteries, supercapacitors and other energy sources
6.1. Challenges faced in developing satisfactory fuel cells for vehicles
6.2. Types of fuel cell and characteristics
8.1. Global market for all batteries for use in portable devices $ billion
8.2. Global market for supercapacitors for use in portable devices $ billion
8.3. Total and small device battery market 2009 and 2019 $billions
8.4. Split of small device battery market in 2009 by shape, giving number, unit value, total value
8.8. Market forecast for printed and potentially printed batteries in US $ billions 2009-2019
FIGURES
1.1. Construction of a battery cell
1.2. MEMS compared with a dust mite less than one millimetre long
1.3. Power in use vs duty cycle for portable and mobile devices showing zones of use of single use vs rechargeable batteries
1.4. Principle of the creation and maintenance of an aluminium electrolytic capacitor
1.5. Construction of wound electrolytic capacitor
1.6. Comparison of construction diagrams of three basic types of capacitor
1.7. Types of ancillary electrical equipment being improved to serve small devices
1.8. Rapid progress in the capabilities of small electronic devices and their photovoltaic energy harvesting contrasted with more modest progress in improving the batteries they employ
2.1. Volumetric energy density vs gravimetric energy density for rechargeable batteries
2.2. Laminar lithium ion battery
2.3. Typical active RFID tag showing the problematic coin cells
2.4. Construction of a lithium rechargeable laminar battery
2.5. Reel to reel construction of rechargeable laminar lithium batteries
2.6. Ultra thin lithium rechargeable battery
2.7. Construction of a thin-film battery
2.8. NanoEnergy® powering a blue LED
2.9. Examples of transparent flexible technology
2.10. Flexible battery that charges in one minute
2.11. Battery assisted passive RFID label with rechargeable thin film lithium battery recording time-temperature profile of food, blood etc in transit
2.12. Bolivian salt flats
2.13. Chevrolet Volt
2.14. Electric Smart car
3.1. Tadiran in EZ pass
3.2. Tadiran’s new high voltage/high rate AA-sized lithium battery
3.3. Internal structure of Power Paper Battery
3.4. Power Paper printed manganese dioxide zinc battery that gathers moisture from the air
3.5. Screen printing of Blue Spark Technology flexible, sealed, manganese dioxide zinc batteries
3.6. Power Paper production line for printed batteries
3.7. Power Paper skin patch that delivers cosmetic through the skin by means of a printed battery and electrodes
3.8. Skin patches electronically communicating to skin patches powered by laminar batteries, coin cells being unacceptable
3.9. Audio Paper TM
3.10. Electronic apparel - sports bra with diagnostic electronics and animated t-shirt displaying music
3.11. Wireless body area network
3.12. Disposable digital plaster
3.13. Sensium system
3.14. Flexible battery made of nanotube ink
3.15. Microbattery built with viruses
3.16. Biomimetic energy storage
4.1. E-labels with capacitor and no battery.
4.2. Examples of small aluminum electrolytic capacitors
4.3. Simplest common modeling circuit for an electrolytic capacitor
5.1. Where supercapacitors fit in
5.2. Energy density vs power density for storage devices
5.3. Small carbon aerogel supercapacitors
5.4. Bikudo supercapacitor
5.5. Laminar supercapacitor one millimetre thick
5.6. Mobile phone modified to give much brighter flash thanks to supercapacitor outlined in red
5.7. Perpetuum energy harvester with its supercapacitors
5.8. Citizen Eco-DriveTM solar powered wristwatch with rechargeable battery
5.9. Symmetric supercapacitor construction
5.10. Symmetric compared to asymmetric supercapacitor construction
5.11. Single sheets of graphene
5.12. Graphene supercapacitor cross section
6.1. MIT Biomimetic fuel cell
6.2. Freeplay wind up radio in Africa
7.1. Blue Spark laminar battery
7.2. Celxpert notebook battery pack
7.3. Interchangeable notebook battery pack
7.4. The Cymbet EnerChip
7.5. Duracell NiOx batteries
7.6. Enfucell SoftBattery
7.7. Thin-film solid-state batteries by Excellatron
7.8. Solar-powered Lifeline radio
7.9. The world’s thinnest self standing rechargeable battery claims FET
7.10. Light in Africa
7.11. LiTESTAR
7.12. Comparison of an electrostatic capacitor, an electrolytic capacitor and an EDLC
7.13. Comparison of an EDLC with an asymmetric supercapacitor sometimes painfully called a bacitor or supercabattery
7.14. Researchers from Planar Energy -Devices, Inc., insert a sample into the vacuum chamber of the company’s thin-film deposition system
7.15. Planar Energy Devices has advanced the solid-state lithium battery from NREL’s crude prototype (below) to a miniaturized, integrated device (bottom)
7.16. Flexible battery that charges in one minute
7.17. Nippon Chemi-Con ELDCs - supercapacitors
7.18. New Planar Energy Devices high capacity laminar battery
7.19. Power Paper’s battery technology
7.20. Prelonic printed batteries

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Batteries-Supercapacitors-Alternative-Storage-for-Portable-Devices.html